尤瑞克林联合依达拉奉治疗急性脑梗死的疗效评价及对hs-CRP的影响

目的观察尤瑞克林联合依达拉奉治疗急性脑梗死的疗效评价及对hs-CRP的影响。方法 60例急性脑梗死患者分为治疗组(尤瑞克林联合依达拉奉治疗)和对照组(依达拉奉治疗)各30例,比较两组患者的疗效及两组治疗前、治疗后7 d、治疗后14 d血清hs-CRP的变化情况。结果治疗组总有效率93.3%,对照组总有效率70.0%,两组疗效比较,差异有统计学意义(P<0.05)。治疗7d后,治疗组及对照组患者的血清hs-CRP水平分别为(31.23±10.38)mg/L、(50.72±11.52)mg/L,分别较治疗前明显降低(t=8.342、3.237,P<0.05);治疗后14d,治疗组及对照组患者的血清hs-CRP水平分别为(9.21±1.43)mg/L、(12.58±1.73)mg/L,分别明显低于治疗后7d hs-CRP水平(t=13.753、10.248,P<0.05);且也分别明显低于治疗前血清hs-CRP水平(t=19.231、13.872,P<0.05)。结论尤瑞克林联合依达拉奉治疗急性脑梗死疗效较好,且无明显不良反应,可以降低hs-CRP水平,值得推广和应用。

The efficacy of urinary kallidinogenase and edaravone in treatment of a- cute cerebral infarction and impact of hs-CRP

Objective To explore the efficacy of urinary kallidinogenase and edaravone in treatment of acute cerebral infarction and impact of hs-CRP, Methods Sixty patients with acute cerebral infarction were divided into treatment group（urinary kallidinogenase and edaravone treatment） and control group（edaravone treatment） of 30 patients each, the efficacy and serum hs-CRP changes were compared after treatment of 7 days and 14 days. Results The total effective rate of the treatment group was 93.3%, and that of the control group was 70.0%, the difference was statistically signifi- cant （P 〈 0.05）. After treatment of 7 days, serum hs-CRP levels of the treatment group and the control group were 31.23±10.38 mg/L, 50.72±11,52 rag/L, respectively, significantly lower than before treatment （t = 8.342, 3.237, P 〈 0.05）; After treatment of 14 days, serum hs-CRP levels of the treatment group and the control group were 9.21±1.43 mg/L, 12.58±1.73 mg/L, respectively, was significantly lower than the hs-CRP level of 7 days after treatment （t = 13.753, 10.248, P 〈 0.05）; and were also significantly lower than serum hs-CRP level of the pre-treatment （t = 19.231, 13.872, P 〈 0.05）. Conclusion Urinary Kallidinogenase and edaravone has better effect in treatment of acute cerebral infarc- tion, and has no significant adverse reactions that can reduce the level of hs-CRP, worthy of promotion and application.